Malignancy and IFITM3: Friend or Foe?

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Cancer prevalence and incidence are increasing, necessitating novel therapeutic targets.
• Despite treatment advances, high mortality and morbidity persist, driving demand for personalized medicine.
• Interferon induced transmembrane protein 3 (IFITM3) is overexpressed in cancers and indicates a poor prognosis.

Purpose of the Study:

• To review recent advances in Interferon induced transmembrane protein 3 (IFITM3) biology.
• To explore IFITM3's regulatory pathways and its role in cancer immunity and stemness.
• To evaluate IFITM3 as a potential therapeutic target in cancer.

Main Methods:

• Literature review of recent studies on IFITM3.
• Analysis of IFITM3 expression in various cancer types.
• Examination of IFITM3's influence on tumorigenic phenotypes and regulatory pathways.

Main Results:

• IFITM3 overexpression correlates with inflammation, immune responses, and epithelial-to-mesenchymal transition (EMT) pathways.
• IFITM3 promotes cancer cell proliferation, migration, and invasion.
• IFITM3 plays a critical role in cancer growth and maintenance, with silencing reducing these effects.

Conclusions:

• IFITM3 is implicated in multiple cancer-promoting mechanisms, including immunity and stemness.
• Targeting IFITM3 presents a promising strategy for developing new cancer therapies.
• Understanding IFITM3 regulation and function is crucial for advancing personalized cancer treatment.